Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hematopoietic and Lymphatic System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm

Cancer Family

Hematopoietic and Lymphatic System Neoplasm

CI-CAN-00000022Explore in graph →

Non-malignant4,304 active trials98 approved drugs1,010 evidence items

NCIt: C35813

Overview
Statistics
Survival
Genomics60
Variants & evidence1010
Drugs99
Trials18827
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (736)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 376–400 of 736 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
· Leuk Res · 2014 · PMID 24836762 · validated civic_curation pubmed
Clinical significance of TP53 mutation in myeloma.
· Leukemia · 2007 · PMID 17215851 · validated civic_curation pubmed
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
· Blood · 2012 · PMID 22215888 · validated civic_curation pubmed
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
· Blood · 2014 · PMID 24740809 · validated civic_curation pubmed
Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
· J Clin Oncol · 2011 · PMID 21747090 · validated civic_curation pubmed
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
· Nat Med · 2013 · PMID 23377281 · validated civic_curation pubmed
Somatic STAT3 mutations in large granular lymphocytic leukemia.
· N Engl J Med · 2012 · PMID 22591296 · validated civic_curation pubmed
Ibrutinib in previously treated Waldenström's macroglobulinemia.

Showing 376–400 of 736 publications

← Previous
1
…
15
16
17
…
30
Next →

· N Engl J Med · 2015 · PMID 25853747 · validated civic_curation pubmed

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

· Blood · 2012 · PMID 22077063 · validated civic_curation pubmed

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

· Lancet Oncol · 2015 · PMID 26256760 · validated civic_curation pubmed

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.

· Br J Haematol · 2016 · PMID 26771088 · validated civic_curation pubmed

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.

· Am J Hematol · 2012 · PMID 22180162 · validated civic_curation pubmed

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

· Nature · 2012 · PMID 22504184 · validated civic_curation pubmed

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

· Blood · 2012 · PMID 22368270 · validated civic_curation pubmed

Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.

· Int J Hematol · 2013 · PMID 23670176 · validated civic_curation pubmed

Assessment of Minimal Residual Disease in Standard-Risk AML.

· N Engl J Med · 2016 · PMID 26789727 · validated civic_curation pubmed

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

· Ann Hematol · 2014 · PMID 24981688 · validated civic_curation pubmed

BRAF mutations in hairy-cell leukemia.

· N Engl J Med · 2011 · PMID 21663470 · validated civic_curation pubmed

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

· Lancet Oncol · 2013 · PMID 23598171 · validated civic_curation pubmed

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.

· Blood Cancer J · 2016 · PMID 27058230 · validated civic_curation pubmed

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

· Nat Med · 2012 · PMID 22426421 · validated civic_curation pubmed

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.

· Leukemia · 2013 · PMID 23018865 · validated civic_curation pubmed

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

· N Engl J Med · 2012 · PMID 23190221 · validated civic_curation pubmed

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.

· Blood · 2004 · PMID 14504092 · validated civic_curation pubmed

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

· Blood · 2008 · PMID 18689542 · validated civic_curation pubmed